Granted Patent B2

US 12,350,343 · App. 17/309,631 · Granted Jul 8, 2025

Inventors: Catherine Stace (Cambridge, GB); Daniel Teufel (Cambridge, GB); Edward Walker (Cambridge, GB)

Assignee: BicycleTx Limited

A61K47/645A61K47/552A61K47/6415C07K7/64

Abstract

Claims (53)

1. A peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a non-aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence:

C i -P-F/I/Y-D/S—W-H-T-C ii -L-F-G-D/E-Y-T/S-C iii (SEQ ID NO: 1)

wherein C i , C ii and C iii represent first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.

2. The peptide ligand as defined in claim 1 , wherein the peptide ligand comprises an amino acid sequence selected from:

(SEQ ID NO: 2)

CPYSWETCLFGDYRC;

(SEQ ID NO: 3)

CPFDWHTCLFGDYTC;

(SEQ ID NO: 4)

CPFDWHTCLFGEYSC;

(SEQ ID NO: 5)

CPIDWHTCLFGDYTC;

(SEQ ID NO: 6)

CPFSWHTCLFGEYSC:

(SEQ ID NO: 7)

CPFSWHTCLFGDYTC;

(SEQ ID NO: 8)

CPISWHTCLFGDYSC;

and

(SEQ ID NO: 9)

CPYSWHTCLFGDYSC.

or a pharmaceutically acceptable salt thereof.

3. The peptide ligand as defined in claim 1 , wherein the molecular scaffold is TATA.

4. The peptide ligand as defined in claim 3 , wherein the molecular scaffold is TATA and the peptide ligand comprises an amino acid sequence selected from:

A-(SEQ ID NO: 3)-A (BCY1057);

A-(SEQ ID NO: 4)-A (BCY1065);

A-(SEQ ID NO: 5)-A (BCY1067);

A-(SEQ ID NO: 6)-A (BCY1073);

A-(SEQ ID NO: 7)-A (BCY1074);

A-(SEQ ID NO: 8)-A (BCY1075); and

A-(SEQ ID NO: 9)-A (BCY1076),

or a pharmaceutically acceptable salt thereof.

5. The peptide ligand as defined in claim 1 , wherein the peptide ligand is a free acid, or a pharmaceutically acceptable salt selected from the sodium, potassium, calcium, and ammonium salt.

6. The peptide ligand as defined in claim 1 , wherein the MT1-MMP is human MT1-MMP.

7. A drug conjugate comprising the peptide ligand as defined in claim 1 , conjugated to one or more effector and/or functional groups, wherein the one or more effector and/or functional groups are one or more cytotoxic agents.

8. The drug conjugate as defined in claim 7 , wherein said cytotoxic agent is selected from MMAE and DM1.

9. A pharmaceutical composition which comprises the peptide ligand of claim 1 , in combination with one or more pharmaceutically acceptable excipients.

10. The pharmaceutical composition as defined in claim 9 , which additionally comprises one or more therapeutic agents.

11. A method for preventing, suppressing or treating a disease or disorder mediated by MT1-MMP in a patient, comprising administering to the patient the drug conjugate as defined in claim 7 .

12. A pharmaceutical composition which comprises the drug conjugate of claim 7 , in combination with one or more pharmaceutically acceptable excipients.

13. The pharmaceutical composition as defined in claim 12 , which additionally comprises one or more therapeutic agents.

14. The peptide ligand as defined in claim 2 , wherein the peptide ligand comprises an amino acid sequence selected from:

A-(SEQ ID NO: 3)-A (BCY1057);

A-(SEQ ID NO: 4)-A (BCY1065);

A-(SEQ ID NO: 5)-A (BCY1067);

A-(SEQ ID NO: 6)-A (BCY1073);

A-(SEQ ID NO: 7)-A (BCY1074);

A-(SEQ ID NO: 8)-A (BCY1075); and

A-(SEQ ID NO: 9)-A (BCY1076),

or a pharmaceutically acceptable salt thereof.

15. A drug conjugate comprising the peptide ligand as defined in claim 1 , conjugated to one or more effector and/or functional groups, wherein each one or more effector and/or functional groups is a metal chelator.

16. The drug conjugate of claim 15 , wherein the metal chelator is complexed to a metal radioisotope.

17. The drug conjugate of claim 16 , wherein the metal radioisotope is selected from 64 Cu, 67 Ga, 68 Ga, 177 Lu, 90 Y, and 213 Bi.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (400)